Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
04:01pm, Thursday, 13'th Jun 2024
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translat
Nkarta: Finally An Attractive Valuation
02:20am, Saturday, 25'th May 2024
Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
04:01pm, Thursday, 09'th May 2024
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today re
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar
06:30am, Tuesday, 07'th May 2024
Three equities stand out among the plethora of alternatives as possible Wall Street game-changers. Each represents a distinct industry: energy, cannabis and biotechnology.
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
10:27am, Saturday, 27'th Apr 2024
NKTX is now down over 50% from its March 2024 highs. The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease. NKTX has already produced some data
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nkarta, Inc.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
05:44pm, Friday, 05'th Apr 2024
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) investors concerning the Company'
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
03:35pm, Friday, 05'th Apr 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) on behalf of investors concerning the Compa
Nkarta to Participate in Upcoming Investor Conferences
04:02pm, Wednesday, 03'rd Apr 2024
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its p
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
08:55am, Sunday, 31'st Mar 2024
Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks.
Nkarta: NK Cell Therapy Advancement On Two Fronts
04:03pm, Monday, 25'th Mar 2024
Release of results from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory NHL, expected mid-2024; this is using a compressed dosing schedule. The global non-Hodgki
Nkarta Announces Pricing of $240 Million Underwritten Offering
06:30am, Monday, 25'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the p
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
04:01pm, Thursday, 21'st Mar 2024
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today
3 Overlooked Stocks Ready to Capture the Market by Storm
07:29am, Tuesday, 19'th Mar 2024
Some overlooked stocks remain obscure and wait for astute investors to spot them. This happens even in the middle of Wall Street's busy trading floors and the digital chaos of online investing platfor
Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders
01:22pm, Wednesday, 13'th Mar 2024
Nkarta's stock soared 690% in six months, buoyed by promising cell therapy technology for cancer and autoimmune diseases. Financially healthy, with a high current ratio and a cash runway extending int
